New Edge Advisors, LLC Arbutus Biopharma Corp Transaction History
New Edge Advisors, LLC
- $16.2 Billion
- Q1 2025
A detailed history of New Edge Advisors, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, New Edge Advisors, LLC holds 500 shares of ABUS stock, worth $1,705. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$1,705% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ABUS
# of Institutions
191Shares Held
111MCall Options Held
866KPut Options Held
608K-
Morgan Stanley New York, NY23.8MShares$81.1 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$45.4 Million27.3% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.4 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.47MShares$32.3 Million1.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$30.5 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $511M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...